Role of nicotinic and muscarinic receptors on synaptic plasticity and neurological diseases

Marco Fuenzalida, Miguel Ángel Pérez, Hugo R. Arias

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The cholinergic activity in the brain is fundamental for cognitive functions. The modulatory activity of the neurotransmitter acetylcholine (ACh) is mediated by activating a variety of nicotinic acetylcholine receptors (nAChR) and muscarinic acetylcholine receptors (mAChR). Accumulating evidence indicates that both nAChR and mAChRs can modulate the release of several other neurotransmitters, modify the threshold of long-term plasticity, finally improving learning and memory processes. Importantly, the expression, distribution, and/or function of these systems are altered in several neurological diseases. The aim of this review is to discuss our current knowledge on cholinergic receptors and their regulating synaptic functions and neuronal network activities as well as their use as targets for the development of new and clinically useful cholinergic ligands. These new therapies involve the development of novel and more selective cholinergic agonists and allosteric modulators as well as selective cholinesterase inhibitors, which may improve cognitive and behavioral symptoms, and also provide neuroprotection in several brain diseases. The review will focus on two nAChR receptor subtypes found in the mammalian brain and the most commonly targeted in drug discovery programs for neuropsychiatric disorder, the ligands of α4β2 nAChR and α7 nAChRs.

Original languageEnglish
Pages (from-to)2004-2014
Number of pages11
JournalCurrent Pharmaceutical Design
Volume22
Issue number14
DOIs
StatePublished - 1 Apr 2016
Externally publishedYes

Fingerprint

Neuronal Plasticity
Nicotinic Receptors
Muscarinic Receptors
Cholinergic Agents
Neurotransmitter Agents
Ligands
Cholinergic Agonists
Behavioral Symptoms
Neurobehavioral Manifestations
Cholinesterase Inhibitors
Brain
Brain Diseases
Cholinergic Receptors
Drug Discovery
Cognition
Acetylcholine
Learning
Therapeutics

Keywords

  • Acetylcholine
  • Muscarinic receptors
  • Neurological disease
  • Nicotinic receptors
  • Synaptic plasticity

Cite this

@article{b27e71d8f0714779a99390ec9477f59c,
title = "Role of nicotinic and muscarinic receptors on synaptic plasticity and neurological diseases",
abstract = "The cholinergic activity in the brain is fundamental for cognitive functions. The modulatory activity of the neurotransmitter acetylcholine (ACh) is mediated by activating a variety of nicotinic acetylcholine receptors (nAChR) and muscarinic acetylcholine receptors (mAChR). Accumulating evidence indicates that both nAChR and mAChRs can modulate the release of several other neurotransmitters, modify the threshold of long-term plasticity, finally improving learning and memory processes. Importantly, the expression, distribution, and/or function of these systems are altered in several neurological diseases. The aim of this review is to discuss our current knowledge on cholinergic receptors and their regulating synaptic functions and neuronal network activities as well as their use as targets for the development of new and clinically useful cholinergic ligands. These new therapies involve the development of novel and more selective cholinergic agonists and allosteric modulators as well as selective cholinesterase inhibitors, which may improve cognitive and behavioral symptoms, and also provide neuroprotection in several brain diseases. The review will focus on two nAChR receptor subtypes found in the mammalian brain and the most commonly targeted in drug discovery programs for neuropsychiatric disorder, the ligands of α4β2 nAChR and α7 nAChRs.",
keywords = "Acetylcholine, Muscarinic receptors, Neurological disease, Nicotinic receptors, Synaptic plasticity",
author = "Marco Fuenzalida and P{\'e}rez, {Miguel {\'A}ngel} and Arias, {Hugo R.}",
year = "2016",
month = "4",
day = "1",
doi = "10.2174/1381612822666160127112021",
language = "English",
volume = "22",
pages = "2004--2014",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "14",

}

Role of nicotinic and muscarinic receptors on synaptic plasticity and neurological diseases. / Fuenzalida, Marco; Pérez, Miguel Ángel; Arias, Hugo R.

In: Current Pharmaceutical Design, Vol. 22, No. 14, 01.04.2016, p. 2004-2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of nicotinic and muscarinic receptors on synaptic plasticity and neurological diseases

AU - Fuenzalida, Marco

AU - Pérez, Miguel Ángel

AU - Arias, Hugo R.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The cholinergic activity in the brain is fundamental for cognitive functions. The modulatory activity of the neurotransmitter acetylcholine (ACh) is mediated by activating a variety of nicotinic acetylcholine receptors (nAChR) and muscarinic acetylcholine receptors (mAChR). Accumulating evidence indicates that both nAChR and mAChRs can modulate the release of several other neurotransmitters, modify the threshold of long-term plasticity, finally improving learning and memory processes. Importantly, the expression, distribution, and/or function of these systems are altered in several neurological diseases. The aim of this review is to discuss our current knowledge on cholinergic receptors and their regulating synaptic functions and neuronal network activities as well as their use as targets for the development of new and clinically useful cholinergic ligands. These new therapies involve the development of novel and more selective cholinergic agonists and allosteric modulators as well as selective cholinesterase inhibitors, which may improve cognitive and behavioral symptoms, and also provide neuroprotection in several brain diseases. The review will focus on two nAChR receptor subtypes found in the mammalian brain and the most commonly targeted in drug discovery programs for neuropsychiatric disorder, the ligands of α4β2 nAChR and α7 nAChRs.

AB - The cholinergic activity in the brain is fundamental for cognitive functions. The modulatory activity of the neurotransmitter acetylcholine (ACh) is mediated by activating a variety of nicotinic acetylcholine receptors (nAChR) and muscarinic acetylcholine receptors (mAChR). Accumulating evidence indicates that both nAChR and mAChRs can modulate the release of several other neurotransmitters, modify the threshold of long-term plasticity, finally improving learning and memory processes. Importantly, the expression, distribution, and/or function of these systems are altered in several neurological diseases. The aim of this review is to discuss our current knowledge on cholinergic receptors and their regulating synaptic functions and neuronal network activities as well as their use as targets for the development of new and clinically useful cholinergic ligands. These new therapies involve the development of novel and more selective cholinergic agonists and allosteric modulators as well as selective cholinesterase inhibitors, which may improve cognitive and behavioral symptoms, and also provide neuroprotection in several brain diseases. The review will focus on two nAChR receptor subtypes found in the mammalian brain and the most commonly targeted in drug discovery programs for neuropsychiatric disorder, the ligands of α4β2 nAChR and α7 nAChRs.

KW - Acetylcholine

KW - Muscarinic receptors

KW - Neurological disease

KW - Nicotinic receptors

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=84969142070&partnerID=8YFLogxK

U2 - 10.2174/1381612822666160127112021

DO - 10.2174/1381612822666160127112021

M3 - Article

C2 - 26818867

AN - SCOPUS:84969142070

VL - 22

SP - 2004

EP - 2014

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 14

ER -